According to a recent LinkedIn post from Saluda Medical, the company has released results for the quarter ended 31 March 2026, describing the period as one of strong commercial progress and growing global adoption of its closed-loop neuromodulation platform. The post cites CEO Barry Regan emphasizing momentum in the business and the continued expansion of the U.S. sales force to increase the number of active implanting physicians.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post also indicates that management feels confident in its ability to scale the commercial organization and has raised FY26 guidance on the back of higher customer demand and investment in sales training and hiring. For investors, the suggestion of upgraded full-year guidance and sustained demand could point to accelerating revenue growth, while broader adoption of the technology may strengthen Saluda Medical’s competitive position in the neuromodulation market.